#United States #Revuforj #Niktimvo #Syndax #Waltham, Massachusetts

Syndax Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals, a notable name in the biopharmaceutical landscape, has announced that its Chief Executive Officer, Michael A. Metzger, will represent the company at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. This event is set to take place on January 14, 2025, where Metzger's presentation will commence at 10:30 AM PT / 1:30 PM ET.

This conference is a premier event in the healthcare sector, attracting industry leaders, investors, and other stakeholders. Syndax, which trades on Nasdaq under the symbol SNDX, aims to highlight its innovative pipeline of cancer therapies, emphasizing advancements in treatment options that mirror the company's dedication to improving patient care.

The Innovative Pipeline of Syndax Pharmaceuticals

Syndax Pharmaceuticals is committed to creating effective cancer therapies, with significant milestones achieved in recent years. Noteworthy products in their pipeline include Revuforj® (revumenib), the first FDA-approved menin inhibitor, which represents a pivotal step in targeted cancer treatment. Additionally, Niktimvo™ (axatilimab-csfr) has also received FDA approval as a monoclonal antibody that effectively blocks the colony-stimulating factor 1 (CSF-1) receptor, playing a crucial role in cancer therapy.

These innovations are a part of Syndax's broader strategy to redefine cancer care and facilitate better treatment outcomes for patients across various types of cancer. The company is proactively involving itself in multiple clinical trials, exploring therapeutics that work across different stages and types of cancer.

Accessing the Presentation and Future Insights

For those unable to attend in person, a live webcast of the presentation will be made available through the Investor Relations section of Syndax's official website at www.syndax.com. After the live event, a replay will be offered for a limited duration, ensuring that a wider audience can engage with the insights and developments shared during the presentation.

About Syndax Pharmaceuticals

Founded with a vision to innovate in the oncology sector, Syndax Pharmaceuticals has rapidly established itself as a leader in developing novel cancer treatments. The company's commitment is not only to bring new therapies to the market but also to challenge conventional cancer treatment paradigms. Syndax believes that groundbreaking approaches in research and development could significantly alleviate the global cancer burden.

As Syndax prepares for its participation in this prestigious event, the focus remains on communicating its progress and future directions in cancer therapy. The J.P. Morgan Healthcare Conference serves as a significant platform for facilitating discussions that could lead to collaborations, investments, and advancements in oncology.

For further updates and in-depth information about Syndax’s initiatives, follow the company on social media platforms like X and LinkedIn. Your engagement and interest in the fight against cancer can lead to broader awareness and support for the innovative work being done in biopharmaceuticals.

In conclusion, Syndax Pharmaceuticals' upcoming presentation at the J.P. Morgan Healthcare Conference symbolizes not only an opportunity to showcase their advancements and therapeutic programs but also their unwavering commitment to reimagining cancer care for a healthier future. This event is sure to highlight the key role of innovative biotechnology in overcoming the challenges posed by cancer today.